Coralville Business Journal: Coralville-based KemPharm this week announced it has entered into a license agreement with KVK Tech Inc. for U.S. commercial rights to its FDA-approved prodrug, Apadaz. KemPharm and KVK will continue to collaborate on pre-launch activities, including outreach and plan adoption by pharmacy benefit managers and managed care organizations for the exclusive use of Apadaz as an alternative to existing hydrocodone/acetaminophen products.